Skip to main content

Table 4 Recent reports on stereotactic body radiation therapy for lung or liver metastases

From: Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence

Aurhor (reference) Lesion /Patients, n CRC rate, % Median f/u period, m Median MTD, mm Median GTV, mL LC, % PFS, % OS, % AE ≥ G3, %
1 yr 2 yr 1 yr 2 yr 1 yr 2 yr
Rusthoven (7) 63/ 38 24 15 NA 4.2 100 96 NA NA NA 39 8
Rurthoven (8) 63/ 47 32 16 27 14.9 95 92 NA NA NA 30 2
Binkley (10) 122/ 77 21 22 NA 3.7 91 84 NA 25 94 75 0
Andratschke (13) 91/ 52 42 17 28 NA NA 82 35 18 70 45 1.9(≥G2)
Ricard (14) 77/ 61 21 20 NA NA NA 89 NA 32 NA 67 2
Filippi (15) 59/ 40 100 46 15 NA 93 NA 49 27 84 73 7.5(≥G2)
Agolli (16) 69/ 44 100 36 14 NA NA NA NA 20 NA 68 0
Katz (17) 74/ 69 29 15 27 NA 76 57 24 NA 78 37 0
Scorsetti (18) 52/ 42 100 24 35 NA 95 91 NA 46 NA 65 0
Joo (19) 103/ 70 100 34 29 NA 93 89 NA 35 NA 75 NA
Wang (25) 134/ 95 18 17 NA 14.6 98 91 51 29 83 61 3
Vautrauers-Dewas (26) 62/ 42 67 14 25 13 90 86 NA NA 94 48 6.3
Present study 114/ 76 61 21 19 3.2 89 78 38 20 96 76 1.3
  1. CRC colorectal cancer, MTD maximum tumor diameter, GTV gross tumor volume, LC local control, PFS progression free survival, OS overall survival, AE adverse event, NA: